Heather A. Lankes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Heather A. Lankes has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Matthew A. Powell
Washington University School of Medicine, St. Louis, MO, USA
4 shared publications - Michael W. Sill
Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA
4 shared publications - Robert S. Mannel
Stephenson Cancer Center at the University of Oklahoma, Gynecologic Oncology, Oklahoma City, OK, USA
4 shared publications - Floor Jenniskens Backes
The Ohio State University 5 Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, College of Medicine Columbus, Ohio
3 shared publications - Kathleen Nadine Moore
University of Nebraska Medical Center, Omaha, NE
3 shared publications - Angeles Alvarez Secord
Duke Cancer Institute 5 Durham, NC
2 shared publications
Latest Publications
- 1 July 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 146 (1) , 137-145
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study
- 1 July 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 146 (1) , 137-145
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study
- 1 May 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 145 (2) , 291-297
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study
- 1 May 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 145 (2) , 291-297
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study
- 1 March 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (3) , 459-467
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study
- 1 March 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (3) , 459-467
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study
- 1 January 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (1) , 96-100
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D
- 1 January 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (1) , 96-100
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D
- 1 January 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (1) , 101-106
A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study
- 1 January 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (1) , 101-106
A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study
- Open Access
Synuclein‐γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study
BACKGROUND: Synuclein‐γ (SNCG) is highly expressed in advanced solid tumors, including uterine serous carcinoma (USC). The objective of the current study was to determine whether SNCG protein was associated with survival and clinical covariates using the largest existing collection of USCs from the Gynecologic Oncology Group (GOG‐8023).METHODS: High‐density tissue microarrays (TMAs) of tumor tissues from 313 patients with USC were stained by immunohistochemistry for SNCG, p53, p16, FOLR1, pERK, pAKT, ER, PR, and HER2/neu. Associations of SNCG and other tumor markers with overall and progression‐free survival were assessed using log‐rank tests and Cox proportional‐hazards models, which also were adjusted for age, race, and stage.RESULTS: The overall survival at 5 years was 46% for women with high SNCG expression and 62% for those with low SNCG expression (log‐rank P = .021; hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.91‐1.9 in adjusted Cox model). The progression‐free survival rate at 5 years was worse for women who had high SNCG expression, at 40%, compared with 56% for those who had low SNCG expression (log‐rank P = .0081; HR, 1.36; 95% CI, 0.96‐1.92 in adjusted Cox model). High levels of both p53 and p16 were significantly associated with worse overall survival (p53: HR, 4.20 [95% CI, 1.54‐11.45]; p16: HR, 1.95 [95% CI, 1.01‐3.75]) and progression‐free survival (p53: HR, 2.16 [95% CI, 1.09‐4.27]; p16: HR, 1.53 [95% CI, 0.87‐2.69]) compared with low levels.CONCLUSIONS: This largest collection of USCs to date demonstrates that SNCG was associated with poor survival in univariate analyses. SNCG does not predict survival outcome independent of p53 and p16 in models that jointly consider multiple markers. Cancer 2017;123:1144–1155. © 2016 American Cancer Society.
Open AccessSynuclein‐γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study
BACKGROUND: Synuclein‐γ (SNCG) is highly expressed in advanced solid tumors, including uterine serous carcinoma (USC). The objective of the current study was to determine whether SNCG protein was associated with survival and clinical covariates using the largest existing collection of USCs from the Gynecologic Oncology Group (GOG‐8023).METHODS: High‐density tissue microarrays (TMAs) of tumor tissues from 313 patients with USC were stained by immunohistochemistry for SNCG, p53, p16, FOLR1, pERK, pAKT, ER, PR, and HER2/neu. Associations of SNCG and other tumor markers with overall and progression‐free survival were assessed using log‐rank tests and Cox proportional‐hazards models, which also were adjusted for age, race, and stage.RESULTS: The overall survival at 5 years was 46% for women with high SNCG expression and 62% for those with low SNCG expression (log‐rank P = .021; hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.91‐1.9 in adjusted Cox model). The progression‐free survival rate at 5 years was worse for women who had high SNCG expression, at 40%, compared with 56% for those who had low SNCG expression (log‐rank P = .0081; HR, 1.36; 95% CI, 0.96‐1.92 in adjusted Cox model). High levels of both p53 and p16 were significantly associated with worse overall survival (p53: HR, 4.20 [95% CI, 1.54‐11.45]; p16: HR, 1.95 [95% CI, 1.01‐3.75]) and progression‐free survival (p53: HR, 2.16 [95% CI, 1.09‐4.27]; p16: HR, 1.53 [95% CI, 0.87‐2.69]) compared with low levels.CONCLUSIONS: This largest collection of USCs to date demonstrates that SNCG was associated with poor survival in univariate analyses. SNCG does not predict survival outcome independent of p53 and p16 in models that jointly consider multiple markers. Cancer 2017;123:1144–1155. © 2016 American Cancer Society.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 5517
A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission.
5517 Background: Phase I data have demonstrated induction of antibody responses to a polyvalent vaccine conjugate (Globo-H, GM2, MUC1-TN, TF) with adjuvant OPT-821. We sought to determine if this combination decreases the hazard of progression versus OPT-821 alone in patients with EOC in second or third clinical complete remission (cCR) following chemotherapy. Secondary objectives were overall survival (OS), safety and immunogenicity. Methods: Patients were randomized (1:1) to receive OPT-821 + vaccine conjugate subcutaneously at weeks 1, 2, 3, 7, 11 and then every 12 weeks (total 11) Dose delay or reduction was not permitted. Patients were removed for pre-defined DLT. Randomized patients were evaluated for efficacy. Results: Between 2010 and 2013 171 patients were randomized; 170 treated. Most received 2 prior regimens (68%), had serous carcinoma (85%), stage 3 disease at diagnosis (77%), and no bevacizumab (67%). 54% received > 6 cycles treatment [median 6 in each arm (p = 0.33)]. 77% of patients discontinued due to progression, 4% due to toxicity, and 1 due to MDS. Maximum toxicity was grade 5 (n = 1, unrelated), grade 4 MDS and depression (n=2, unlikely), grade 3 GI disorders + others (n = 20, 4 related). Most common lesser adverse events were injection site reactions (84%) and fever (19%). (+) immunogenicity is defined as 1:40 or two fold increase. Estimated hazard ratio for PFS of vaccine conjugate + OPT-821 to OPT-821 arm was 0.98 (95% CI: 0.71-1.36). At followup of 34 months, median OS for OPT-821 is 47 months and not reached for vaccine conjugate + OPT-821. Conclusions: Vaccination with this polyvalent construct was modestly immunogenic and does not prolong PFS when compared to OPT-821 alone. The secondary OS endpoint requires additional followup. The second and third remission cohort is a feasible and well defined population to explore innovative consolidation or maintenance approaches. Clinical trial information: NCT00857545.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 5517
A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission.
5517 Background: Phase I data have demonstrated induction of antibody responses to a polyvalent vaccine conjugate (Globo-H, GM2, MUC1-TN, TF) with adjuvant OPT-821. We sought to determine if this combination decreases the hazard of progression versus OPT-821 alone in patients with EOC in second or third clinical complete remission (cCR) following chemotherapy. Secondary objectives were overall survival (OS), safety and immunogenicity. Methods: Patients were randomized (1:1) to receive OPT-821 + vaccine conjugate subcutaneously at weeks 1, 2, 3, 7, 11 and then every 12 weeks (total 11) Dose delay or reduction was not permitted. Patients were removed for pre-defined DLT. Randomized patients were evaluated for efficacy. Results: Between 2010 and 2013 171 patients were randomized; 170 treated. Most received 2 prior regimens (68%), had serous carcinoma (85%), stage 3 disease at diagnosis (77%), and no bevacizumab (67%). 54% received > 6 cycles treatment [median 6 in each arm (p = 0.33)]. 77% of patients discontinued due to progression, 4% due to toxicity, and 1 due to MDS. Maximum toxicity was grade 5 (n = 1, unrelated), grade 4 MDS and depression (n=2, unlikely), grade 3 GI disorders + others (n = 20, 4 related). Most common lesser adverse events were injection site reactions (84%) and fever (19%). (+) immunogenicity is defined as 1:40 or two fold increase. Estimated hazard ratio for PFS of vaccine conjugate + OPT-821 to OPT-821 arm was 0.98 (95% CI: 0.71-1.36). At followup of 34 months, median OS for OPT-821 is 47 months and not reached for vaccine conjugate + OPT-821. Conclusions: Vaccination with this polyvalent construct was modestly immunogenic and does not prolong PFS when compared to OPT-821 alone. The secondary OS endpoint requires additional followup. The second and third remission cohort is a feasible and well defined population to explore innovative consolidation or maintenance approaches. Clinical trial information: NCT00857545.
- 1 February 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 140 (2) , 264-269
The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study
- 1 February 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 140 (2) , 264-269
The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study